Sentien Biotechnologies, Inc.

10:45 AM - 11:00 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Sentien Biotechnologies, Inc. is a privately-owned, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, encapsulates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. This design allows for extended exposure of patient blood to the MSCs, resulting in the dynamic delivery of MSC-secreted factors at doses that are unattainable by direct injection.

SBI-101 is being evaluated in a Phase Ib/IIa study in subjects with dialysis-requiring acute kidney injury (AKI-D). An interim readout from the study supports safety and provides early evidence of anti-inflammatory effects consistent with the SBI-101 therapeutic hypothesis. Sentien plans to expand its pipeline to include additional systemic inflammatory indications where single-factor agents have not been effective, in both the acute and chronic disease spaces.
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
SBI-101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided